Tissue Regenix Group Management
Management criteria checks 2/4
Tissue Regenix Group's CEO is Danny Lee, appointed in Nov 2020, has a tenure of 4.08 years. total yearly compensation is $621.00K, comprised of 49.1% salary and 50.9% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth £168.09K. The average tenure of the management team and the board of directors is 4.1 years and 8.4 years respectively.
Key information
Danny Lee
Chief executive officer
US$621.0k
Total compensation
| CEO salary percentage | 49.1% |
| CEO tenure | 4.1yrs |
| CEO ownership | 0.4% |
| Management average tenure | 4.1yrs |
| Board average tenure | 8.4yrs |
Recent management updates
Recent updates
Does Tissue Regenix Group (LON:TRX) Have A Healthy Balance Sheet?
Nov 02
Tissue Regenix Group plc's (LON:TRX) Share Price Is Matching Sentiment Around Its Revenues
Jun 01Tissue Regenix Group plc's (LON:TRX) Shares Bounce 25% But Its Business Still Trails The Industry
Feb 25Is Tissue Regenix Group (LON:TRX) A Risky Investment?
Jun 10Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?
Apr 02Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?
Nov 18
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$1m |
| Mar 31 2024 | n/a | n/a | -US$1m |
| Dec 31 2023 | US$621k | US$305k | -US$2m |
| Sep 30 2023 | n/a | n/a | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$2m |
| Dec 31 2022 | US$581k | US$290k | -US$3m |
| Sep 30 2022 | n/a | n/a | -US$3m |
| Jun 30 2022 | n/a | n/a | -US$4m |
| Mar 31 2022 | n/a | n/a | -US$4m |
| Dec 31 2021 | US$503k | US$290k | -US$5m |
| Sep 30 2021 | n/a | n/a | -US$8m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$306k | US$38k | -US$12m |
Compensation vs Market: Danny's total compensation ($USD621.00K) is above average for companies of similar size in the UK market ($USD349.06K).
Compensation vs Earnings: Danny's compensation has increased whilst the company is unprofitable.
CEO
Danny Lee (63 yo)
4.1yrs
Tenure
US$621,000
Compensation
Mr. Daniel Ray Lee, also known as Danny, serves as Chief Executive Officer and Director at Tissue Regenix Group plc since November 16, 2020. He was President, US Operations at Tissue Regenix Group plc sinc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.1yrs | US$621.00k | 0.40% £ 168.1k | |
| CFO & Executive Director | 3.9yrs | US$367.00k | 0.22% £ 91.9k | |
| Technical & Operations Director - UK | no data | no data | no data | |
| Senior Vice President | no data | no data | no data | |
| EMEA Business Director & Company Secretary | 5yrs | no data | 0.16% £ 67.6k |
4.1yrs
Average Tenure
Experienced Management: TRX's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.1yrs | US$621.00k | 0.40% £ 168.1k | |
| CFO & Executive Director | 3.9yrs | US$367.00k | 0.22% £ 91.9k | |
| Independent Non-Executive Director | 3.9yrs | US$44.00k | 0.22% £ 95.2k | |
| Member of Orthopedic Clinical Advisory Board for US | 8.4yrs | no data | no data | |
| Independent Non-Executive Director | 3.9yrs | US$44.00k | 0.085% £ 35.9k | |
| Non-Executive Chairman | 8.9yrs | US$87.00k | 0.57% £ 241.6k | |
| Independent Non-Executive Director | 8.5yrs | US$37.00k | 0.023% £ 9.7k | |
| Member of Orthopedic Clinical Advisory Board for US | 8.4yrs | no data | no data | |
| Member of Orthopedic Clinical Advisory Board for US | 8.4yrs | no data | no data | |
| Member of Orthopedic Clinical Advisory Board for US | 8.4yrs | no data | no data | |
| Member of Orthopedic Clinical Advisory Board for US | 8.4yrs | no data | no data |
8.4yrs
Average Tenure
63yo
Average Age
Experienced Board: TRX's board of directors are considered experienced (8.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 18:46 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tissue Regenix Group plc is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Brewer | Cavendish |
| Christopher Donnellan | Cavendish |
| Vadim Alexandre Khalil | Daniel Stewart & Company |